CONy 2024 | Will long-term anti-amyloid treatment show greater clinical benefit?

Dorota Religa, MD, PhD, Karolinska Institutet, Solna, Sweden, discusses her thoughts on the possibility that clinical benefit of anti-amyloid therapies might become apparent with longer-term use. There is currently no evidence on use beyond 18 months, so data are needed to definitively answer this question. Prof. Religa notes that patient registries will be a valuable resource when investigating the effectiveness of long-term treatment. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.